>중동 및 아프리카 레버 선천성 흑내장 시장, 질병 유형(유아형, 청소년형 및 기타), 유형(치료 및 진단), 최종 사용자(병원, 전문 클리닉, 외래 수술 센터, 가정 의료 및 기타), 유통 채널(직접 입찰 및 소매 판매)별 산업 동향 및 2029년까지의 예측.
시장 분석 및 통찰력
중동 및 아프리카 레버 선천성 아마우로시스 시장은 당뇨병 및 위장 장애와 같은 만성 질환의 유병률 증가, 신생 기업의 증가, 가정 간병 서비스에서 주입 펌프의 인기와 같은 요인에 의해 주도되며, 이는 수요를 증가시키고 연구 개발에 대한 투자 증가로 이어지며 시장 성장으로 이어집니다. 현재 다양한 연구 조사가 진행 중이며, 이는 제조업체가 새롭고 혁신적인 레버 선천성 아마우로시스 치료법과 요법을 개발할 수 있는 경쟁 우위를 창출할 것으로 예상되며, 이는 레버 선천성 아마우로시스 시장에서 다양한 다른 기회를 제공할 것으로 예상됩니다. 그러나 주입 요법 중 승인 및 장치 오류에 대한 엄격한 정부 규정은 성장을 방해할 것으로 예상됩니다.
중동 및 아프리카 레버 선천성 아마우로시스 시장 보고서는 시장 점유율, 새로운 개발 및 제품 파이프라인 분석, 국내 및 현지 시장 참여자의 영향, 새로운 수익 주머니, 시장 규정의 변화, 제품 승인, 전략적 의사 결정, 제품 출시, 지리적 확장 및 시장의 기술 혁신 측면에서의 분석 기회에 대한 세부 정보를 제공합니다. 분석 및 시장 시나리오를 이해하려면 분석가 브리핑을 위해 저희에게 연락하세요. 저희 팀은 보장된 지불과 제품의 높은 국제 판매로 인해 고객 사이에서 선호도가 높아지는 원하는 목표를 달성하기 위한 수익 영향 솔루션을 만드는 데 도움을 드릴 것입니다. 이는 예측 기간 동안 시장 수요를 촉진한 주요 요인입니다.
중동 및 아프리카 레버 선천성 아마우로시스 시장은 지지적이며 질병의 진행을 줄이는 것을 목표로 합니다. Data Bridge Market Research는 중동 및 아프리카 레버 선천성 아마우로시스 시장이 2022년에서 2029년까지의 예측 기간 동안 2.7%의 CAGR로 성장할 것이라고 분석합니다.
|
보고서 메트릭 |
세부 |
|
예측 기간 |
2022년부터 2029년까지 |
|
기준 연도 |
2021 |
|
역사적 연도 |
2020 (2019-2014까지 사용자 정의 가능) |
|
양적 단위 |
수익은 백만 달러, 가격은 미화로 표시됨 |
|
다루는 세그먼트 |
질병 유형(유아형, 청소년형 및 기타), 유형(치료, 진단), 최종 사용자(병원, 전문 클리닉, 외래 수술 센터 , 가정 의료 및 기타), 유통 채널(직접 입찰 및 소매 판매) 별 |
|
적용 국가 |
국가별(사우디 아라비아, 남아프리카, UAE, 이스라엘, 쿠웨이트, 이집트, 기타 중동 및 아프리카) |
|
시장 참여자 포함 |
Invitae Corporation, Spark Therapeutics, Inc., LKC Technologies, CENTOGENE N.V., Optos, Metrovision, Blue Print Genetics Oy (A Subsidiary of Quest Diagnostics), CD Genomics, ProQR Therapeutics, OCUGEN, INC., MeiraGTx Limited, Coave Therapeutics, IVERIC bio, Inc. , Atsena Therapeutics, Editas Medicine, Eluminex Biosciences, Okuvision, Astellas Pharma Inc., Allergan, agtc, Gyroscope Therapeutics Limited, SparingVision, Kubota Pharmaceutical Holdings Co. Ltd., REGENXBIO Inc. among others. |
Middle East and Africa Leber Congenital Amaurosis Market Dynamics
Drivers
- Increase in incidence and prevalence of rpe65 gene-mediated in retinal diseases
Inherited retinal dystrophies (IRDs) represent a genetically diverse group of progressive, visually debilitating diseases. Adult and pediatric patients with vision loss due to IRD caused by biallelic mutations in the 65-kDa retinal pigment epithelium (RPE65) gene are often clinically diagnosed as retinitis pigmentosa (RP), and leber congenital amaurosis (LCA).
Leber congenital amaurosis (LCA) is an eye disorder that primarily affects the retina. LCA is characterized by severe visual impairment from birth or the first few months of life, roving eye movements or nystagmus, poor pupillary light responses, oculo digital sign (poking, rubbing, and/or pressing of the eyes), and undetectable or severely abnormal full-field electroretinogram (ERG). LCA is usually inherited as an autosomal recessive genetic condition.
- Increase in pipeline products and clinical trials
The continuous innovation for the treatment of inherited retinal diseases and leber congenital amaurosis disorder has the potential to positively impact the market as the size of the market will increase, when these products will have approved in the market. Due to no pharmacological treatments for the LCA the major market players are continuously innovating the treatment or investing in the R&D for the treatment. Various ongoing clinical trials are recruiting worldwide to find the mechanism of diseases for treatment.
Opportunities
- Increase in government initiatives toward leber congenital amaurosis
According to WHO, the prevalence of monogenic IRDs is it affects about 1 in 40,000 newborns ly. To prevent these, the government of several countries across the globe have taken initiatives.
The various programs and decisions taken by the government around the world for giving the best treatment to their population is the major factor that is expected to increase the demand and will act as an opportunity for the leber congenital amaurosis market.
Restraints/Challenges
The cost of the product plays a major factor in the market. In the inherited retinal diseases market, it is generally observed that the cost of the products is highly sophisticated, need to be precise, and other specifications increase the product's cost.
The high cost of the treatment is due to the various checkpoints of the treatment along with the use of high-tech modalities to perform such treatment procedures.
However, the hospital care further adds to the cost of the leber congenital amaurosis. As the cost of innovative and advanced products is high, the cost of the treatment proportionally gets escalated, due to which high cost associated with leber congenital amaurosis treatment and diagnosis is expected to restrain the leber congenital amaurosis market growth.
Whereas the European Medicines Agency does not. Gene therapy products are regulated by FDA’s Center for Biologics Evaluation and Research (CBER). FDA requires the submission of an IND before initiating clinical studies, and an approved biologics license application (BLA) to market the product in the United States. The regulatory framework for the development and manufacturing of gene therapy products comprises regulations and guidance documents, including the interpretation of these governing documents by regulators.
However, every country is bounded by the guidelines regulated by different authorities which are expected to act as a challenge to the growth of the leber congenital amaurosis market.
Recent Development
- In March 2022, SparingVision announced that it will be presenting data on its lead product candidate SPVN06 and the natural history of retinitis pigmentosa, its core focus indication, at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting. This has helped the company to showcase its progress on pipeline products.
Middle East and Africa Leber Congenital Amaurosis Market Divide
Middle East and Africa leber congenital amaurosis market is categorized into five notable segments which are based on disease type, type, end-user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Disease Type
- Infantile Type
- Juvenile Type
- Others
On the basis of disease type, the leber congenital amaurosis market is segmented into infantile type, juvenile type & others
Type
- Diagnosis
- Therapy
유형별로 레버 선천성 아마우로시스 시장은 진단과 치료로 세분화됩니다. 진단 세그먼트는 임상 진단과 유전적 진단으로 세분화됩니다. 임상 진단은 임상적 안구 검사, 시야 검사, 소매 영상 및 전기 생리학적 검사로 세분화됩니다. 임상 진단은 전기 생리학적 검사, 망막 영상, 시야 검사 및 임상적 안구 검사로 세분화됩니다. 전기 생리학 검사는 전체 시야 전기 망막 검사(ERG) 및 암흑 적응 검사(DA)로 세분화됩니다. 망막 영상은 광 간섭 단층 촬영(OCT), 안저 자가 형광 영상(FAF), 주사 레이저 검안경 검사(SLO) 및 적응 광학(AO) 영상 및 기존 컬러 안저 영상으로 세분화됩니다. 시야 검사는 컴퓨터화된 시야 검사와 수동 시야 검사로 세분화됩니다. 임상 검사는 슬릿 램프, 간접 검안경 검사, 굴절 검사 및 확장 검사로 세분화됩니다. 치료 세그먼트는 유전자 치료, 망막 치료, 신경 보호제 등으로 세분화됩니다. 유전자 치료는 룩스투르나 등으로 세분화됩니다. 신경 보호제는 비타민 A 팔미테이트, 도코사헥사엔산(DHA), 루테인 등으로 세분화됩니다.
최종 사용자
- 병원
- 전문 병원
- 외래 수술 센터
- 홈 헬스케어
- 기타
레버 선천성 흑암시 시장은 최종 사용자를 기준으로 병원, 전문 병원, 외래 수술 센터, 가정 의료 서비스 및 기타로 구분됩니다.
유통 채널
- 소매 판매
- 직접 입찰
유통 채널을 기준으로 레버 선천성 흑암시 시장은 소매 판매, 직접 입찰로 세분화됩니다.
Leber 선천성 아마우로시스 시장 지역 분석/통찰력
레버 선천성 흑암시 시장을 분석하고, 위에 언급된 대로 국가, 질병 유형, 유형, 최종 사용자 및 유통 채널별로 시장 규모에 대한 통찰력과 추세를 제공합니다.
레버 선천성 흑내장 시장 보고서에서 다루는 국가는 사우디아라비아, 남아프리카공화국, UAE, 이스라엘, 쿠웨이트, 이집트, 기타 중동 및 아프리카입니다.
주요 국가의 전략적 이니셔티브가 강화되면서 남아프리카공화국이 우위를 점할 것으로 예상됩니다.
보고서의 국가 섹션은 또한 현재 및 미래 시장 추세에 영향을 미치는 개별 시장 영향 요인과 시장 규제의 변화를 제공합니다. 다운스트림 및 업스트림 가치 사슬 분석, 기술 추세 및 포터의 5가지 힘 분석, 사례 연구와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 몇 가지 포인터입니다. 또한 글로벌 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 국내 관세 및 무역 경로의 영향은 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.
경쟁 환경 및 레버 선천성 아마우로시스 시장 점유율 분석
중동 및 아프리카 레버 선천성 아마우로시스 시장 경쟁 구도는 경쟁자에 대한 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 중동 및 아프리카의 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 프로그램 우세입니다. 제공된 위의 데이터 포인트는 회사의 초점 레버 선천성 아마우로시스 시장에만 관련이 있습니다.
주요 기업으로는 Invitae Corporation, Spark Therapeutics, Inc., LKC Technologies, CENTOGENE NV, Optos, Metrovision, Blue Print Genetics Oy(Quest Diagnostics의 자회사), CD Genomics, ProQR Therapeutics, OCUGEN, INC., MeiraGTx Limited, Coave Therapeutics, IVERIC bio, Inc., Atsena Therapeutics, Editas Medicine, Eluminex Biosciences, Okuvision, Astellas Pharma Inc., Allergan, agtc, Gyroscope Therapeutics Limited, SparingVision, Kubota Pharmaceutical Holdings Co. Ltd., REGENXBIO Inc. 등이 있습니다.
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석 및 추정됩니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 기본(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 이 외에도 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 회사 시장 점유율 분석, 측정 표준, 중동 및 아프리카 대 지역 및 공급업체 점유율 분석이 포함됩니다. 추가 문의 사항이 있는 경우 분석가 전화를 요청하십시오.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 DISEASE TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PIPELINE ANALYSIS FOR MIDDLE EAST & AFRICA LEBER CONGENTIAL AMAUROSIS MARKET
4.2 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: REGULATIONS
4.3 PESTEL ANALYSIS
4.4 PORTERS FIVE FORCES
5 EPIDEMIOLOGY
6 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET, MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASE IN INCIDENCE AND PREVALENCE OF RPE65 GENE-MEDIATED IN RETINAL DISEASES
6.1.2 INCREASE IN PIPELINE PRODUCTS AND CLINICAL TRIALS
6.1.3 INCREASE IN STRATEGIC INITIATIVE BY KEY PLAYER
6.2 RESTRAINTS
6.2.1 LACK OF QUALIFIED PROFESSIONALS
6.2.2 HIGH COSTS ASSOCIATED WITH TREATMENT AND PROCEDURE
6.3 OPPORTUNITIES
6.3.1 INCREASE IN GOVERNMENT INITIATIVES TOWARD LEBER CONGENITAL AMAUROSIS
6.3.2 INCREASE IN THE TREATMENT-SEEKING RATE
6.3.3 FAVOURABLE REIMBURSEMENT POLICIES FOR THE TREATMENT
6.4 CHALLENGES
6.4.1 RISKS ASSOCIATED WITH LEBER CONGENITAL AMAUROSIS GENE THERAPY
6.4.2 STRINGENT GOVERNMENT REGULATIONS FOR GENE THERAPY PRODUCTS
7 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE
7.1 OVERVIEW
7.2 INFANTILE TYPE
7.3 JUVENILE TYPE
7.4 OTHERS
8 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE
8.1 OVERVIEW
8.2 THERAPY
8.2.1 GENE THERAPY
8.2.1.1 LUXTURNA
8.2.2 RETINAL PROSTHETIC
8.2.3 NEUROPROTECTIVE AGENTS
8.2.3.1 VITAMIN A PALMITATE
8.2.3.2 DOCOSAHEXAENOIC ACID
8.2.3.3 LUTEIN
8.2.3.4 OTHERS
8.2.4 OTHERS
8.3 DIAGNOSIS
8.3.1 CLINICAL DIAGNOSIS
8.3.1.1 ELECTROPHYSIOLOGICAL TESTS
8.3.1.1.1 FULL-FIELD ELECTRORETINOGRAM (ERG)
8.3.1.1.2 DARK ADAPTOMETRY (DA)
8.3.1.2 RETINAL IMAGING
8.3.1.2.1 OPTICAL COHERENCE TOMOGRAPHY (OCT)
8.3.1.2.2 FUNDUS AUTOFLUORESCENCE
8.3.1.2.3 SCANNING LASER OPHTHALMOSCOPY (SLO)
8.3.1.2.4 ADAPTIVE OPTICS (AO) IMAGING
8.3.1.2.5 CONVENTIONAL COLOR FUNDUS IMAGING
8.3.1.3 VISUAL FIELD TEST
8.3.1.3.1 COMPUTERIZED VISUAL FIELD TESTS
8.3.1.3.2 MANUAL FIELD TEST
8.3.1.4 CLINICAL EYE EXAMINATION
8.3.1.4.1 SLIT LAMP
8.3.1.4.2 INDIRECT OPHTHALMOSCOPY
8.3.1.4.3 REFRACTION TEST
8.3.1.4.4 DILATION EXAM
8.3.1.5 OTHERS
8.3.2 GENETIC DIAGNOSIS
9 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER
9.1 OVERVIEW
9.2 HOSPITALS
9.3 SPECIALITY CLINICS
9.4 AMBULATORY SURGICAL CENTERS
9.5 HOME HEALTHCARE
9.6 OTHERS
10 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL
10.1 OVERVIEW
10.2 RETAIL SALES
10.2.1.1 HOSPITAL PHARMACIES
10.2.1.2 RETAIL PHARMACIES
10.2.1.3 OTHERS
10.3 DIRECT TENDER
11 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY REGION
11.1 MIDDLE EAST AND AFRICA
11.1.1 SOUTH AFRICA
11.1.2 SAUDI ARABIA
11.1.3 U.A.E
11.1.4 ISRAEL
11.1.5 EGYPT
11.1.6 KUWAIT
11.1.7 REST OF MIDDLE EAST AND AFRICA
12 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 SPARK THERAPEUTICS, INC
14.1.1 COMPANY SNAPSHOT
14.1.2 COMPANY SHARE ANALYSIS
14.1.3 PRODUCT PORTFOLIO
14.1.4 RECENT DEVELOPMENT
14.1.4.1 EU AUTHORIZATION
14.2 OPTOS
14.2.1 COMPANY SNAPSHOT
14.2.2 COMPANY SHARE ANALYSIS
14.2.3 PRODUCT PORTFOLIO
14.2.4 RECENT DEVELOPMENT
14.2.4.1 PRODUCT APPROVAL
14.3 CD GENOMICS
14.3.1 COMPANY SNAPSHOT
14.3.2 COMPANY SHARE ANALYSIS
14.3.3 PRODUCT PORTFOLIO
14.3.4 RECENT DEVELOPMENT
14.4 BLUEPRINTS GENETICS OY (A SUBSIDIARY OF QUEST DIAGNOSTICS)
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENTS
14.4.5.1 COLLABORATION
14.5 LKC TECHNOLOGIES, INC
14.5.1 COMPANY SNAPSHOT
14.5.2 COMPANY SHARE ANALYSIS
14.5.3 PRODUCT PORTFOLIO
14.5.4 RECENT DEVELOPMENT
14.5.4.1 PRODUCT APPROVAL
14.5.5 PRODUCT APPROVAL
14.6 AGTC
14.6.1 COMPANY SNAPSHOT
14.6.2 REVENUE ANALYSIS
14.6.3 PRODUCT PORTFOLIO
14.6.4 RECENT DEVELOPMENTS
14.6.4.1 AGREEMENT
14.7 ALLERGAN (A SUBSIDIARY OF ABBVIE INC.)
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENTS
14.8 ASTELLAS PHARMA INC.
14.8.1 COMPANY SNAPSHOT
14.8.2 REVENUE ANALYSIS
14.8.3 PRODUCT PORTFOLIO
14.8.4 RECENT DEVELOPMENT
14.9 ATSENA THERAPEUTICS
14.9.1 COMPANY SNAPSHOT
14.9.2 PRODUCT PORTFOLIO
14.9.3 RECENT DEVELOPMENT
14.1 CENTOGENE N.V.
14.10.1 COMPANY SNAPSHOT
14.10.2 REVENUE ANALYSIS
14.10.3 PRODUCT PORTFOLIO
14.10.4 RECENT DEVELOPMENT
14.10.4.1 PRODUCT LAUNCH
14.11 COAVE THERAPEUTICS
14.11.1 COMPANY SNAPSHOT
14.11.2 PRODUCT PORTFOLIO
14.11.3 RECENT DEVELOPMENT
14.12 EDITAS MEDICINE
14.12.1 COMPANY SNAPSHOT
14.12.2 REVENUE ANALYSIS
14.12.3 PRODUCT PORTFOLIO
14.12.4 RECENT DEVELOPMENTS
14.12.4.1 DATA & TRAIL DATA PRESENTATION
14.13 ELUMINEX BIOSCIENCES
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 RECENT DEVELOPMENT
14.14 GYROSCOPE THERAPEUTICS LIMITED
14.14.1 COMPANY SNAPSHOT
14.14.2 PRODUCT PORTFOLIO
14.14.3 RECENT DEVELOPMENTS
14.15 INVITAE CORPORATION
14.15.1 COMPANY SNAPSHOT
14.15.2 REVENUE ANALYSIS
14.15.3 PRODUCT PORTFOLIO
14.15.4 RECENT DEVELOPMENTS
14.15.4.1 NEW FACILITY
14.15.4.2 EXPANSION
14.16 IVERIC BIO.
14.16.1 COMPANY SNAPSHOT
14.16.2 PRODUCT PORTFOLIO
14.16.3 RECENT DEVELOPMENT
14.17 KUBOTA PHARMACEUTICAL HOLDINGS CO., LTD.
14.17.1 COMPANY SNAPSHOT
14.17.2 REVENUE ANALYSIS
14.17.3 PRODUCT PORTFOLIO
14.17.4 RECENT DEVELOPMENTS
14.18 MEIRAGTX LIMITED
14.18.1 COMPANY SNAPSHOT
14.18.2 PRODUCT PORTFOLIO
14.18.3 RECENT DEVELOPMENT
14.19 METROVISION
14.19.1 COMPANY SNAPSHOT
14.19.2 PRODUCT PORTFOLIO
14.19.3 RECENT DEVELOPMENT
14.19.3.1 FDA CLEARANCE APPROVAL
14.2 OCUGEN INC.
14.20.1 COMPANY SNAPSHOT
14.20.2 PRODUCT PORTFOLIO
14.20.3 RECENT DEVELOPMENT
14.21 OKUVISION
14.21.1 COMPANY SNAPSHOT
14.21.2 PRODUCT PORTFOLIO
14.21.3 RECENT DEVELOPMENTS
14.21.3.1 APPROVAL
14.22 PROQR THERAPEUTICS
14.22.1 COMPANY SNAPSHOT
14.22.2 PRODUCT PORTFOLIO
14.22.3 RECENT DEVELOPMENTS
14.23 REGENXBIO INC.
14.23.1 COMPANY SNAPSHOT
14.23.2 REVENUE ANALYSIS
14.23.3 PRODUCT PORTFOLIO
14.23.4 RECENT DEVELOPMENTS
14.24 SPARINGVISION
14.24.1 COMPANY SNAPSHOT
14.24.2 PRODUCT PORTFOLIO
14.24.3 RECENT DEVELOPMENTS
15 QUESTIONNAIRE
16 RELATED REPORTS
표 목록
TABLE 1 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 2 MIDDLE EAST & AFRICA INFANTILE TYPE IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 MIDDLE EAST & AFRICA JUVENILE TYPE IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 MIDDLE EAST & AFRICA OTHERS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 6 MIDDLE EAST & AFRICA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 MIDDLE EAST & AFRICA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 8 MIDDLE EAST & AFRICA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 9 MIDDLE EAST & AFRICA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 10 MIDDLE EAST & AFRICA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 MIDDLE EAST & AFRICA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 12 MIDDLE EAST & AFRICA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 13 MIDDLE EAST & AFRICA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 14 MIDDLE EAST & AFRICA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 17 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 18 MIDDLE EAST & AFRICA HOSPITALS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 MIDDLE EAST & AFRICA SPECIALITY CLINICS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA AMBULATORY SURGICAL CENTERS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA HOME HEALTHCARE IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA OTHERS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 24 MIDDLE EAST & AFRICA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 MIDDLE EAST & AFRICA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 26 MIDDLE EAST & AFRICA DIRECT TENDER IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 29 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 30 MIDDLE EAST AND AFRICA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 31 MIDDLE EAST AND AFRICA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 32 MIDDLE EAST AND AFRICA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 33 MIDDLE EAST AND AFRICA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 34 MIDDLE EAST AND AFRICA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 35 MIDDLE EAST AND AFRICA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 42 SOUTH AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 43 SOUTH AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 44 SOUTH AFRICA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 45 SOUTH AFRICA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 46 SOUTH AFRICA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 47 SOUTH AFRICA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 48 SOUTH AFRICA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 49 SOUTH AFRICA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 50 SOUTH AFRICA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 51 SOUTH AFRICA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 52 SOUTH AFRICA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 53 SOUTH AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 54 SOUTH AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 55 SOUTH AFRICA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 56 SAUDI ARABIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 57 SAUDI ARABIA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 58 SAUDI ARABIA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 59 SAUDI ARABIA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 60 SAUDI ARABIA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 61 SAUDI ARABIA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 62 SAUDI ARABIA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 63 SAUDI ARABIA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 64 SAUDI ARABIA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 65 SAUDI ARABIA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 66 SAUDI ARABIA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 67 SAUDI ARABIA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 68 SAUDI ARABIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 69 SAUDI ARABIA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 70 U.A.E LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 71 U.A.E LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 72 U.A.E THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 73 U.A.E GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 74 U.A.E NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 75 U.A.E DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 76 U.A.E CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 77 U.A.E RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 78 U.A.E ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 79 U.A.E VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 80 U.A.E CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 81 U.A.E LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 82 U.A.E LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 83 U.A.E RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 84 ISRAEL LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 85 ISRAEL LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 86 ISRAEL THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 87 ISRAEL GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 88 ISRAEL NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 89 ISRAEL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 90 ISRAEL CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 91 ISRAEL RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 92 ISRAEL ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 93 ISRAEL VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 94 ISRAEL CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 95 ISRAEL LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 96 ISRAEL LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 97 ISRAEL RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 98 EGYPT LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 99 EGYPT LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 100 EGYPT THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 101 EGYPT GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 102 EGYPT NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 103 EGYPT DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 104 EGYPT CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 105 EGYPT RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 106 EGYPT ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 107 EGYPT VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 108 EGYPT CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 109 EGYPT LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 110 EGYPT LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 111 EGYPT RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 112 KUWAIT LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 113 KUWAIT LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 114 KUWAIT THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 115 KUWAIT GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 116 KUWAIT NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 117 KUWAIT DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 118 KUWAIT CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 119 KUWAIT RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 120 KUWAIT ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 121 KUWAIT VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 122 KUWAIT CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 123 KUWAIT LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 124 KUWAIT LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 125 KUWAIT RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 126 REST OF MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
그림 목록
FIGURE 1 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: END USER GRID
FIGURE 9 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: SEGMENTATION
FIGURE 11 RISING GOVERNMENT AWARENESS PROGRAMS ABOUT THE INHERITED RETINAL DISEASE IS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 INFANTILE TYPE IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET IN 2022 & 2029
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES FOR THE MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET
FIGURE 15 PROPORTION OF RPE65 GENE MUTATION IN CLINICALLY DIAGNOSED LCA PATIENTS
FIGURE 16 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE, 2021
FIGURE 17 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE, 2022-2029 (USD MILLION)
FIGURE 18 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE, CAGR (2022-2029)
FIGURE 19 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 20 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY TYPE, 2021
FIGURE 21 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 22 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 23 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 24 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, 2021
FIGURE 25 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 26 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, CAGR (2022-2029)
FIGURE 27 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, LIFELINE CURVE
FIGURE 28 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 29 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 30 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, CAGR (2022-2029)
FIGURE 31 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, LIFELINE CURVE
FIGURE 32 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET: SNAPSHOT (2021)
FIGURE 33 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2021)
FIGURE 34 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 35 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 36 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE (2022-2029)
FIGURE 37 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: COMPANY SHARE 2021 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
